Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

CellMax Life Shares Positive Results From Validation Study for FirstSight™ Blood Test for Detection of Colorectal Cancer and Pre-cancerous Advanced Adenomas


News provided by

CellMax Life

Jan 26, 2024, 09:30 ET

Share this article

Share toX

Share this article

Share toX

Dr. Shai Friedland of Stanford Medicine presented the latest results of FirstSight™  at ASCO GI 2024
Dr. Shai Friedland of Stanford Medicine presented the latest results of FirstSight™ at ASCO GI 2024

CellMax Life, a molecular diagnostics company with proprietary technology for pre-cancer and cancer detection blood tests, presented the latest results from its independent external validation study on January 20, 2024 at the ASCO Gastrointestinal Cancers Symposium. Data from this external validation study showed that FirstSight™ was able to detect CRC with 92% sensitivity and advanced adenomas (AA) with a 53% sensitivity, increasing to 66% for adenomas with high-grade dysplasia and 69% for large adenomas ≥3cm in size. These results demonstrate best-in-class performance and increase in significance when compared to stool tests and first-generation liquid biopsy tests.

SUNNYVALE, Calif., Jan. 26, 2024 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with proprietary technology for pre-cancer and cancer detection blood tests, presented the latest results from its independent external validation study on January 20, 2024 at the ASCO Gastrointestinal Cancers Symposium.

The study used a predefined and locked assay, algorithm and clinical threshold developed from the previous N1038 model development study to evaluate the performance of FirstSight™ in an independent external validation set with subjects not previously tested. A demographically representative, majority intended-use average risk cohort of 449 subjects across 15 sites in the U.S. and 1 site in Canada were analyzed in the external validation set.

"The results from this external validation study are incredibly promising; a blood test that can detect early-stage colorectal cancer and advanced adenomas with high sensitivity along with vastly improved screening rates has the potential to pre-empt progression to cancer." - Shai Friedland, MD

Post this

Data from this external validation study showed that FirstSight™ was able to detect CRC with 92% sensitivity and advanced adenomas (AA) with a 53% sensitivity, increasing to 66% for adenomas with high-grade dysplasia and 69% for large adenomas ≥3cm in size. These results demonstrate best-in-class performance and increase in significance when compared to stool tests and first-generation liquid biopsy tests.

"There is a significant unmet clinical need when it comes to detecting colorectal cancer and advanced adenomas," said Shai Friedland, MD, lead principal investigator on the study and gastroenterologist at Stanford Medicine. "The challenges come because stool tests and alternative options such as routine colonoscopies have low compliance. The results from this external validation study are incredibly promising; a blood test that can detect early-stage colorectal cancer and advanced adenomas with high sensitivity along with vastly improved screening rates has the potential to pre-empt progression to cancer."

The FirstSight™ blood test is uniquely different from all other ctDNA blood tests and is able to detect advanced adenomas by combining molecular and cellular signatures not just from ctDNA but also from rare epithelial cells shed from adenomas using the company's proprietary circulating epithelial cells (CEC) technology.

"There are too many unnecessary deaths from colorectal cancer," said Atul Sharan, co-founder and CEO of CellMax Life. "Our goal with FirstSight™ continues to be to provide a screening blood test which has not only high sensitivity for colorectal cancer, but also improved detection of advanced adenomas to facilitate targeted colonoscopies for removal and prevent cancer, to the approximately 50 million people who don't follow the American Cancer Society guidelines for screening."

Data from this study, and from previous publications and abstracts, continues to highlight FirstSight's™ ability to detect both CRC and advanced adenomas, and suggests results would be reproducible in a large clinical study. CellMax received the expedited pathway Breakthrough Device Designation from the U.S. Food and Drug Administration in Q3 2021 for FirstSight™.

The company plans to begin a PMA study for an advanced adenoma-only test that the FDA may consider as an adjunct to guideline-approved CRC screening tests to improve CRC prevention. If approved, the highly sensitive, noninvasive FirstSight™ blood test will help increase routine screening compliance for patients who are reluctant to undergo a colonoscopy or stool testing and may help prevent colorectal cancer by detecting the disease earlier when treatment success and survival rates are much higher.

About CellMax Life
CellMax Life is a molecular diagnostics company focused on cancer screening with proprietary technology for detecting precancerous and cancer cells and genomic aberrations in a single blood sample. CellMax Life is headquartered in Sunnyvale, California. For more information, visit http://www.cellmaxlife.com.

Media Contact

Stephen Su, CellMax Life, 1 408-359-7819, [email protected], www.cellmaxlife.com 

SOURCE CellMax Life

Modal title

CRC and AA sensitivity comparison between FirstSight™ vs. FIT and mtDNA-stool tests
CRC and AA sensitivity comparison between FirstSight™ vs. FIT and mtDNA-stool tests
CRC and AA sensitivity comparison between FirstSight™ vs. FIT and mtDNA-stool tests

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.